Patients
Data were collected retrospectively from the medical records of patients with pemphigus diseases who had received rituximab. All patients had an established diagnosis of pemphigus vulgaris or pemphigus foliaceus (included within this subgroup was 1 patient with pemphigus herpetiformis) according to clinical, immunofluorescence, and histopathologic criteria. Initial indications for rituximab treatment were severe relapsing or recalcitrant disease that was refractory to treatment and/or a contraindication to the use of corticosteroids or other immunosuppressive therapy. Data regarding disease, previous treatment, and response to treatment were collected.
Treatment Protocol
Rituximab was administered using a fixed-dose modification of the RA protocol (1 g intravenously on days 1 and 15, with a subsequent dose of 1 g or 500 mg intravenously administered 6 months or more after induction if clinically warranted). In 1 patient, the initial dose received was 1 g only on day 1; this was because an adverse reaction prohibited administration of the day 15 dose. Most patients continued to receive concomitant adjuvant corticosteroid or immunosuppressive treatment during cycle 1. The expectation was to discontinue adjuvant treatments if there was an adequate response to rituximab. We aimed to repeat treatment in patients who experienced relapse after achieving remission with rituximab. Use of rituximab was subject to financial constraints by third-party payers, such as insurance companies and the provincial health care system. A compassionate use program sponsored by the manufacturer (Roche Pharma) aided many of our patients.
Assessment of Response to Treatment
Response to treatment was determined according to the definitions of an international consensus statement. 16 
Outcome Measures
We examined response to treatment, times to relapse, and adverse reactions. The primary end points were time to failure and complete remission with or without treatment. Secondary end points included adverse events, long-term follow-up, and the number of treatment cycles received.
Statistical Analysis
Baseline characteristics and categorical variables were summarized using descriptive statistics and compared with the unpaired 2-tailed t test, χ 2 , or Kruskal-Wallis test as appropriate.
Progression-free survival was calculated from the date of rituximab initiation to the date of documented disease progression, relapse, or the end date of the study. Survival curves were created by the Kaplan-Meier method; overall differences were compared by the log-rank test. P < .05 was considered to indicate statistical significance. The data were analyzed using SPSS, version 19.0 for Windows (SPSS, Inc).
Results

Patients
The characteristics of the 92 study patients are presented in Table 1 . Eighty-four patients (91%) had pemphigus vulgaris and 8 had pemphigus foliaceus. Fifty-five patients (60%) were female. The median (range) age at diagnosis was 43 (13-77) years. The age at the start of the first rituximab treatment cycle was 47 (17-77) years. The median disease duration before rituximab treatment was 24 (0-256) months. All but 1 patient was treated with systemic therapies (corticosteroids or immunosuppressive medications) before rituximab treatment. Seventysix patients (83%) were receiving either systemic corticosteroids or immunosuppressive therapies at the time of first rituximab infusion. Although disease scores were not prospectively determined, all patients had severe and/or refractory disease that led to rituximab therapy.
Treatment First Treatment Cycle
After rituximab therapy all patients experienced an improvement in their disease activity. Seventy-four patients (80%) achieved CR either with or without adjuvant treatment; this included 63 individuals (68%) receiving concomitant corticosteroids and 64 patients (70%) receiving concomitant immunosuppressives. After the first cycle, there were 56 relapses (61%) ( Table 2) .
Median time to relapse was 15 months (95% CI, 10.3-19.7) (Figure, A). When comparing time to relapse for pemphigus vulgaris and pemphigus foliaceus, there was no statistically significant difference. The pemphigus vulgaris median time to relapse was 15 months (95% CI, 8.6-21.4), and the pemphigus foliaceus median time to relapse was 12 months (1.5-22.5; P = .99).
Adjuvant Treatment
Patients who received adjuvant treatment had a shorter time to relapse (mean, 12 months; 95% CI, 8.5-15.5) compared with those who did not receive adjuvant therapy, with the median not yet reached at last follow-up (mean, 40.6 months; 95% CI, 34.2-46.9; P = .001) (Figure, B) .
Further Treatment Cycles
The details of additional treatment cycles are reported in Table 2 . Fifty-four patients (24%) received 2 or more cycles, 22 patients (59%) received 3 cycles, 7 patients (8%) received 4 cycles, and 1 patient (1%) each received 5, 6, and 7 cycles in total. There were too few cases after 4 cycles from which to draw meaningful conclusions. There was no significant variance in the time intervals between cycles 1 and 2 (P = .32) and cycles 2 and 3 (P = .60). However, the numbers of patients receiving corticosteroids decreased with progressive cycles (P < .001), as did the numbers of patients receiving concomitant immunosuppressive therapies (P < .001). For patients receiving 3 or more cycles, 95% or more gained CR with or without concomitant treatment.
Relapse
Thirty-six patients (39%) who received just 1 rituximab cycle did not experience relapse. Thirty-five of these individuals (38%) remained in complete remission with or without treatment at last follow-up. Status at 6 months after initiation of treatment cycles demonstrated that there was a significantly lower proportion of relapses after the second and third cycles compared with the first cycle (P < .05) ( Table 2) .
No Prior Systemic Immunosuppressive Therapy
Four patients did not receive prior systemic immunosuppressive therapy, and 3 patients received prior oral corticosteroid treatment. After the first treatment cycle, 4 patients attained a CR. One patient who received only corticosteroids before rituximab experienced relapse after 7 months and received a second cycle; however, all 4 patients remained in CR at the time of the last follow-up.
Adverse Effects of Treatment
No serious infectious adverse events were reported. Infusion reactions were reported in 15 patients (16%). In only 1 patient (1%) did this warrant cessation of treatment (chest tightness toward the end of the infusion). Overall, there were 8 occurrences (9%) of rash/pruritus, 5 occurrences (5%) of throat irritation, 2 episodes (2%) of chest tightness, and 1 each of headache (1%), dizziness (1%), and hypotension (1%). Most (61%) reactions occurred during the first treatment cycle. One patient developed bilateral paronychia after the rituximab infusion. Two patients developed biopsy-confirmed lichen planus (1 case of oral and 1 of annular lichen planus) 3 to 6 months after a rituximab infusion. Status at Last Follow-up At the time of the last follow-up, 56 patients were in CR (61%), 26 were in CROT (28%), 2 experienced PR (2%), 3 developed PROT (3%), and 5 experienced relapse/flare (5%); CR rates with or without adjuvant treatment were 89%. All 5 patients (5%) who had experienced relapse had previously been in remission (2 had achieved CR and 3 had attained CROT); all were awaiting further rituximab therapy.
Long-term Follow-up
A subgroup of 15 patients had at least a 45-month follow-up (Supplement [eTable]). All had received prior systemic immunosuppressive therapy. The median duration of follow-up was 51 months (range, 45-78 months). The median time from diagnosis to rituximab administration was 40 months (range, 1-151 months), and the median time to treatment failure was 19 months (range, 6-78 months). All patients achieved CR at some point during follow-up (CR, 73%; CROT, 27%).
Overall Response to Treatment
Overall, 64 patients (70%) achieved CR during their follow-up and 26 experienced CROT (28%). The best response for 1 patient (1%) was PR and, for another patient, PROT (1%).
Deaths
Two deaths occurred during follow-up. Neither of these deaths was deemed related to rituximab therapy. The first patient had colon cancer with metastatic deposits in the liver, and the second patient had a preexisting thoracic aortic thrombus.
Discussion
Our results show that the fixed-dose modified RA protocol is effective in the treatment of pemphigus disorders. After a single first cycle, 74 patients (80%) achieved the study end points, with almost one-third achieving complete remission while not receiving treatment. Median time to relapse was 15 months (95% CI, 10.3-19.7). Thirty-six patients (39%) never experienced relapse. Patients who received adjuvant treatment had a shorter time to relapse (12 months; 95% CI, 8.5-15.5; P = .001).
Overall, 70% of patients achieved CR at some point during treatment. Rituximab was well tolerated; there were no serious infectious adverse effects reported, although an infusion reaction prevented further treatment in 1 patient. The short-term efficacy of rituximab has been confirmed in several studies. 13, 17 Long-term follow-up has not been examined in as much detail. Reguiai et al 18 showed that rituximab appeared to be a durable, effective, and well-tolerated treatment for severe pemphigus. Mean follow-up was 41 months after the first cycle and 28 months after the last. Similarly, Cianchini et al 14 demonstrated the efficacy of rituximab with a median follow-up of 26.5 months. Recently, Colliou et al 11 reported that rituximab therapy can induce durable remission lasting up to 6 years. This is thought to be due in part to the reshaping of the B-cell repertoire during reconstitution. They found that nearly two-thirds of patients achieved a longterm complete response with or without concomitant therapy. We again have confirmed the short-term efficacy of rituximab and, in a subgroup of patients, have demonstrated longterm efficacy.
There is increasing evidence that rituximab may be useful as a first-line therapy. Lunardon 15 observed that rituximab therapy early in the course of disease is significantly more likely to lead to complete disease remission with no or minimal therapy. This is supported by the evidence presented by Research Original Investigation Fixed Dose of Rituximab for Pemphigus a greater proportion of naive and transitional B cells than did those with incomplete response, suggesting a barrier to B-cell maturation. Complete responders also had a specific loss of antidesmoglein-specific cells, but not B cells, that respond to infections. If all of this information is confirmed in larger studies, this could lead the way for use of rituximab as a first-line therapy. In our study, patients who received adjuvant rituximab therapy had a shorter time to relapse. This may be explained by several reasons: (1) these patients may have more severe disease; (2) there may be a hypothetical effect of sustained immunosuppression on immunosurveillance, permitting the subsequent development of an abnormal B-cell repertoire; or (3) these patients may represent a group that for unknown reasons has abnormal barriers to B-cell maturation. The optimal dosing regimen for rituximab in autoimmune disorders has yet to be determined. 4 In our study, the RA protocol was adapted for use in autoimmune bullous disorders. 19 This protocol has not been used as widely as the lymphoma protocol, but it has been reported 13, 20 as being efficacious and well tolerated. We used a modified version of the RA protocol in clinical practice, and in some instances, patients did not receive the full 1-g dose on days 1 and 15 but rather received doses of 1 g or 500 mg as needed 6 months or more after induction dosing. This occurred when deemed appropriate by the treating physician or by necessity when, because of financial constraints, the full dose was not affordable for the patient. Other studies have reported successful use of low-dose rituximab; in a prospective cohort study, 21 2 infusions of 500 mg at an interval of 2 weeks were administered in 15 patients, with more than half of the patients achieving CR. The rate of adverse effects in our cohort was comparable to that in other reports. 9, 20 In contrast to other studies specifically using the RA protocol, 4 we observed no serious infectious adverse events. As in other reports, 22 an infusion reaction in one of our patients prevented the completion of treatment.
The limitations of our study include the retrospective design, the small numbers of patients with disease entities other than pemphigus vulgaris, and the potential for confounding factors (eg, patients with more refractory disease likely required more adjuvant treatment). The relationship between disease severity and relapse could not be determined because severity was not measured on a consistent basis. We did not quantify immunologic factors before and after treatment in every patient. In most patients, there was a limited follow-up time. Despite these limitations, this is the largest reported series of patients who received rituximab for pemphigus diseases, and it provides information specifically on the use of the fixed-dose RA protocol.
Pemphigus vulgaris and pemphigus foliaceus are chronic autoimmune bullous disorders associated with a significant morbidity and in some cases mortality. Rituximab has provided a major advance for patients who can gain access to it. In some instances, rituximab may be curative. 11 The future looks positive, and with increasing evidence, rituximab may become available as a first-line treatment. There is also an emerging argument for the use of rituximab as a maintenance therapy. 23 Confirmation of the efficacy of rituximab in patients with pemphigus is required in larger and controlled trials. All of the studies discussed in the present report were retrospective; thus, there can be selection bias in how treatments are administered. Issues remain regarding the financial constraints and funding by health payers for rituximab. A favorable economic profile of rituximab has been assessed in treatment of other diseases. 24 Modification of rituximab dosage, low-dose maintenance therapy, and possibly even use as first-line therapy may be solutions to avoid the expense of long-term corticosteroidinduced morbidity and the high cost some of the alternative immunosuppressive agents.
Conclusions
Our experience shows that rituximab is an effective therapy for severe or refractory autoimmune bullous diseases. The modified, fixed-dose RA protocol for rituximab was efficacious and well tolerated in patients with pemphigus. Patients who do not achieve remission after 1 cycle or patients who experience relapse benefit from further cycles. Rituximab appears to be a safe therapeutic option with minimal serious adverse effects. Our results add further validity to the evaluation of rituximab as firstline treatment of autoimmune bullous disorders.
